ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Gastrointestinal Disorders Associated with Long-term Use of Acetylsalicylic Acid in Patients with Stable Ischemic Heart Disease: Characteristics and Treatment Options

DOI:10.31550/1727-2378-2018-152-8-25-29
Bibliography link: Borovkova N.Yu., Buyanova M.V., Bakka T.E., Borovkov N.N., Ivanchenko E.Yu. Gastrointestinal Disorders Associated with Long-term Use of Acetylsalicylic Acid in Patients with Stable Ischemic Heart Disease: Characteristics and Treatment Options. Doctor.Ru. 2018; 8(152): 25–29. DOI: 10.31550/1727-2378-2018-152-8-25-29
25 October 15:48

The number of patients with ischemic heart disease (IHD) is steadily increasing worldwide. They all need long-term therapy with antiplatelet agents, primarily acetylsalicylic acid (ASA). Simultaneously there has been an increase in the number of patients taking ASA who experience gastrointestinal mucosal damage. Intense efforts are therefore being made to find ways to protect the gastric and duodenal mucosa from the effects of ASA. Enteric-coated ASA formulations reduce the risk of mucosal damage but do not eliminate it completely. Proton-pump inhibitors (PPI) and H2-receptor antagonists likewise fail to ensure complete healing of defects in the gastrointestinal mucosa. Misoprostol, a synthetic analogue of prostaglandin E1 (PGE1), is difficult to use and has a number of undesirable side effects. Moreover, it is expensive, which also hinders its wide use. In 2016 Rebamipide, an agent stimulating the production of endogenous prostaglandins, was launched in the Russian market. Trials have demonstrated its good efficacy in treating gastrointestinal mucosal defects of various origin. Thus, it is a promising option for the prevention and treatment of erosive and ulcerative lesions in the gastrointestinal tract, associated with long-term ASA use by IHD patients.

N.Yu. Borovkova — Volga Medical Research University, Russian Ministry of Health, Nizhny Novgorod. E-mail: borovkov-nn@mail.ru

M.V. Buyanova — Volga Medical Research University, Russian Ministry of Health, Nizhny Novgorod. E-mail: buyanova.250@gmail.com

T.E. Bakka — N.A. Semashko Nizhny Novgorod Regional Clinical Hospital, Russian Ministry of Health. E-mail: medic.89@list.ru

N.N. Borovkov — Volga Medical Research University, Russian Ministry of Health, Nizhny Novgorod. E-mail: borovkov-nn@mail.ru

E.Yu. Ivanchenko — Volga Medical Research University, Russian Ministry of Health, Nizhny Novgorod. E-mail: ivanchenkonino15@yandex.ru

Доктор.ру
25 October 15:48
LITERATURE
  1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–71. DOI: 10.1016/S0140-6736(17)32152-9
  2. Townsend N., Wilson L., Bhatnagar Р., Wickramasinghe K., Rayner M., Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur. Heart. J. 2016; 37(42): 3232–45. DOI: 10.1093/eurheartj/ehw334
  3. Демографический ежегодник России. 2015: Стат. сб. Росстат. M.; 2015. 263 с. [Demograficheskij ezhegodnik Rossii. 2015: Stat. sb. Rosstat. M., 2015. 263 s. (in Russian)] 4. Информационный бюллетень ВОЗ № 310, 2014. [Informacionnij byulleten' VOZ № 310, 2014. (in Russian)]
  4. Бокарев И.Н., Попова Л.В. Безопасность разных форм ацетилсалициловой кислоты в профилактике сердечно-сосудистых заболеваний. Consilium Medicum. 2014; 05: 79–84. [Bokarev I.N., Popova L.V. Bezopasnost' raznyh form acetilsalicilovoj kisloty v profilaktike serdechno-sosudistyh zabolevanij. Consilium Medicum. 2014; 05: 79-84. (in Russian)]
  5. Орлова Я.А. Некоторые вопросы назначения ацетилсалициловой кислоты в клинической практике. Артериальная гипертензия. 2015; 21(5): 536–44. [Orlova Ya.A. Nekotorye voprosy naznacheniya acetilsalicilovoj kisloty v klinicheskoj praktike. Arterial'naya gipertenziya. 2015; 21(5): 536–44. (in Russian)]
  6. Емелина Е.И. Баланс пользы и риска при терапии антиагрегантами. Сердце: журнал для практикующих врачей. 2015; 14(1): 34–40. [Emelina E.I. Balans pol'zy i riska pri terapi i antiagregantami. Serdce: zhurnal dlya praktikuyushchih vrachej. 2015; 14(1): 34–40. In Russian)]
  7. Остроумова О.Д., Фомина В.М., Шорикова Е.Г. Ацетилсалициловая кислота в первичной и вторичной профилактике сердечно-сосудистых осложнений: все ли вопросы решены? Атмосфера. Новости кардиологии. 2012; 3: 20–4. [Ostroumova O.D., Fomina V.M., SHorikova E.G. Acetilsalicilovayakislota v pervichnoj i vtorichnoj profilaktike serdechno-sosudistyh oslozhnenij: vse li voprosy resheny ? Atmosfera. Novosti kardiologii. 2012; 3: 20–4. In Russian)]
  8. Комаров А.Л. Гастроэнтеропатии, связанные с приемом ацетилсалициловой кислоты: как повысить безопасность лечения. Рациональная фармакотерапия в кардиологии. 2009; 4: 65–72. [Komarov A.L. Gastroehnteropatii, svyazannye s priemom acetilsalicilovoj kisloty: kak povysit' bezopasnost' lecheniya. Racional'naya Farmakoterapiya v Kardiologii. 2009; 4: 65–72. (in Russian)]
  9. Левых А.Э., Мамчур А.И. Ацетилсалициловая кислота как эффективная и безопасная основа антиагрегантной терапии. Артериальная гипертензия. 2015; 6: 57–63. [Levyh A.E., Mamchur A.I. Acetilsalicilovaya kislotakakehffektivnaya i bezopasnaya osnova antiagregantnoj terapii. Arterial'naya gipertenziya. 2015; 6: 57–63. (in Russian)]
  10. Дроздов В.Н., Ким В.А. Эффективность и безопасность применения ацетилсалициловой кислоты. Рациональная фармакотерапия в фармакологии. 2010; 6: 212–215. [Drozdov V.N., Kim V.A. Effektivnost' i bezopasnost' primeneniya acetilsalicilovoj kisloty. Racional'naya farmakoterapiya v farmakologii. 2010; 6: 212–215. (in Russian)]
  11. Collaborative overview of randomised of antiplateled therapy — I: Prevention of death, myocardial infarction and stroke by prolonged antiplateled therapy in various categories of patients. Antiplatelet Trialists`Collaboration. BMJ. 2014; 308(6921): 81–106.
  12. Lanas A., Perez-Aisa M.A., Feu F., Ponce J., Saperas E., Santolaria S. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non steroidalantiinflammatorydrug use. Am. J. Gastroenterol. 2015; 100(8): 1685–93. DOI: 10.1111/j.1572-0241.2005.41833.x
  13. Tamura A. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin gastroprotective agents: the OITA-GF study. QJM. 2011; 104(2): 133–9. DOI: 10.1093/qjmed/hcq169
  14. Yamagata M. Prevalence and incidence ofNSAID-induced gastro­intestinal ulcers and bleeding. Nihon. Rinsho. 2014; 65(10): 1749–53.
  15. Самсонов А.А., Андреев Д.Н. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49–54. [Samsonov A.A., Andreev D.N. Gastropatii, inducirovannye nesteroidnymi protivovospalitel'nymi sredstvami: patogeneticheski obosnovannye podhody k profilaktike i terapii. Farmateka. 2016; 2: 49–54. (in Russian)]
  16. Маев И.В., Андреев Д.Н., Дичева Д.Т., Жиляев Е.В. Новые представления о гастропатии, ассоциированной с применением нестероидных противовоспалительных препаратов. Consilium Medicum. 2017; 19(8): 12–20. [Maev I.V., Andreev D.N., Dicheva D.T., ZHilyaev E.V. Novye predstavleniya o gastropatii, associirovannoj primeneniem nesteroidnyh protivovospali­tel'nyh preparatov. Consilium Medicum. 2017; 19(8): 12–20. (in Russian)]
  17. Serrano P., Lanas A., Arroyo M.T., Ferreira I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther. 2002; 16(11): 1945–53.
  18. Pignone M., Alberts M.J., Colwell J.A., Cushman M., Inzucchi S.E., Mukherjee D. et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. Circulation. 2010; 121(24): 2694–701. DOI: 10.1161/CIR.0b013e3181e3b133
  19. Корнеева О.Н., Драпкина О.М. Профилактика желудочно-кишечных осложнений при приеме антитромбоцитарных препаратов. Доказательная гастроэнтерология. 2012; 2: 77–81. [Korneeva O.N., Drapkina O.M. Profilaktika zheludochno-kishechnyh oslozhnenij pri prieme antitrombocitarnyh preparatov. Dokazatel'naya gastroehnterologiya, 2012; 2: 77–81. (in Russian)]
  20. Henry D., Dobson A., Turner C. Variability in the risk of major gastrointestinal complications from non aspirinnonsteroidal anti-inflammatory drugs. Gastroenerology. 2010; 105(4): 1078–88. 22. Kubler W., Darius H. Primary prevention of coronary heart disease with aspirin. J. Kardiol. 2015; 94(3): 66–73. DOI: 10.1007/s00392-005-1309-8
  21. Kelly J.P., Kaufman D.W., Jurgelon J.M., Watson R.G.P., Sheehan J., Koff R.S., Shapiro S. Risck of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996; 348(9039): 1413–6. DOI: 10.1016/S0140-6736(96)01254-8
  22. Клинические рекомендации Российской гастроэнтерологичес­кой ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка, вызванных приемом нестероидных противовоспалительных препаратов. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 6: 89–94. [Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniyu erozivno-yazvennykh porazhenii zheludka, vyzvannykh priemom nesteroidnykh protivovospalitel'nykh preparatov. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 6: 89–94. (in Russian)]
  23. Жиров И.В. Длительная терапия ацетилсалициловой кислотой. Что можно сделать для повышения эффективности и безопасности. Трудный пациент. 2013; 5: 8–12. [Zhirov I.V. Dlitel'naya terapiya acetilsalicilovoj kislotoj. Chto mozhno sdelat' dlya povysheniya ehffektivnosti i bezopasnosti. Trudnyj pacient. 2013; 5: 8–12. (in Russian)]
  24. Yeomans N.D., Tulassay Z., Juhász L., Rácz I., Howard J.M., van Rensburg C.J. et al. A comparison of omeprazole with ranitidine for ulcers associated with non steroidalantiinflammatory drugs. Acid Suppression Trial: Rani­tidine versus Omeprazolefor NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N. Engl. J. Med. 2014; 338(11): 719–26. DOI: 10.1056/NEJM199803123381104
  25. Kuroda М., Yoshida N., Ichikawa H., Takagi T., Okuda T., Naito Y. et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indo­methacin-induced rat enteritis. Int. J. Mol. Med. 2006; 17(1): 89–93.
  26. Pozzoli C., Menozzi A., Grandi D., Solenghi E., Ossiprandi M.C., Zullian C. et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn Schmiedebergs Arch. Pharmacol. 2017; 374(4): 283–91. DOI: 10.1007/s00210-006-0121-y
  27. Wallace J.L., Syer S., Denou E., de Palma G., Vong L., McKnight W. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011; 141(4): 1314–22, 1322.e1–5. DOI: 10.1053/j.gastro.2011.06.075
  28. Lamberts R., Brunner G., Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001; 64(4): 205–13. DOI: 10.1159/000048863
  29. Silverstein F.E., Graham D.Y., Senior J.R., Davies H.W., Struthers B.J., Bittman R.M. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non steroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1995; 123(4): 241–9.
  30. Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K., Furberg C.D. et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J. Am. Coll. Cardiol. 2008; 52(18): 1502–17. DOI: 10.1016/j.jacc.2008.08.002
  31. Becker J.S., Domschke W., Pohle T. Current approaches to prevent NSAID-induced gastropathy — COX selectivity and beyond. Br. J. Clin. Pharmacol. 2014; 58(6): 587–600. DOI: 10.1111/j.1365-2125.2004.02198.x
  32. Yamasaki K., Ishiyama H., Imaizumi Т., Kanbe T., Yabuuchi Y. Еffect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn. J. Pharmacol. 2016; 49(4): 441–8.
  33. Zhang S., Qing Q., Bai Y., Mao H., Zhu W., Chen Q. et al. Rebamipide helps defend against non steroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and metaanalysis. Dig. Dis. Sci. 2013; 58(7): 1991–2000. DOI: 10.1007/s10620-013-2606-0
  34. Park S.H., Cho C.S., Lee O.Y., Jun J.B., Lin S.R., Zhou L.Y. et al. Comparison of prevention of NSAIDinduced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J. Clin. Biochem. Nutr. 2007; 40(2): 148–55. DOI: 10.3164/jcbn.40.148
  35. Kurokawa S., Katsuki S., Fujita T., Saitoh Y., Ohta H., Nishikawa K. et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non steroidal anti-inflammatory drug induced small bowel injury. J. Gastroenterol. 2014; 49(2): 239–44. DOI: 10.1007/s00535-013-0805-2
  36. Li W., Zhao Y., Xu X., Ma W., Gao P., Wang Y. et al. Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 2015; 282(12): 2317–26. DOI: 10.1111/febs.13278
  37. Watanbe T., Sugimore S., Kameda N., Machida H., Okazaki H., Tanigawa T. et al. Small bowel injury by low-dose entericcoated aspirin and treatment with misoptostol: a pilot study. Clin. Gastroenterol. Hepatol. 2008; 6(11): 1279–82. DOI: 10.1016/j.cgh.2008.06.021
  38. Ross-Lee L.M., Elms M.J., Cham B.E., Bochner F., Bunce I.H., Eadie M.J. Plasma levels of aspirin following effervescent and ente­ric coated tablets, and their effect on platelet function. Eur. J. Clin. Pharmacol. 1982; 23(6): 545–51.
  39. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. 2010; 4(3): 261–70. DOI: 10.1586/egh.10.25
  40. Watanabe T., Takeuchi T., Handa О., Sakata Y., Tanigawa T., Shiba M. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirininduced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330. DOI: 10.1371/journal.pone.0122330
  41. Moon S.J., Park J.S., Woo Y.J., Lim M.A., Kim S.M., Lee S.Y. et al. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and hemeoxygenase 1 induction. Arthritis Rheumatol. 2014; 66(4): 874–85. DOI: 10.1002/art.38310
  42. Kohata Y., Nakahara K., Tanigawa T., Yamagami H., Shiba M., Watanabe T. et al. Rebamipide alters the esophageal microbiome and reduces the incidence of Barrett's esophagus in a rat model. Dig. Dis. Sci. 2015; 60(9): 2654–61. DOI: 10.1007/s10620-015-3662-4
  43. Mizukami K., Murakami K., Hirashita Y., Hisamatsu A., Ogawa R., Uchida M. et al. Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms. J. Clin. Biochem. Nutr. 2012; 51(3): 216–20. DOI: 10.3164/jcbn.12-27
  44. Mizukami K., Murakami K., Abe T., Inoue K., Uchida M., Okimoto T. et al. Aspirininduced small bowel injuries and the preventive effect of rebamipide. World J. Gastroenterol. 2011; 17(46): 5117–22. DOI: 10.3748/wjg.v17.i46.5117
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News